Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: BioCardia is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its primary focus is the CardiAMP autologous mononuclear cell therapy platform for ischemic heart failure (HFrEF) and chronic myocardial ischemia (CMI), delivered via the Helix transendocardial biotherapeutic delivery system. The company also advances an allogeneic mesenchymal stem cell (MSC) platform for heart failure and acute respiratory distress syndrome (ARDS).
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenue | $0 | $58 |
| Research & Development Expenses | $4,962 | $4,387 |
| Selling, General & Administrative Expenses | $3,316 | $3,672 |
| Net Loss | $(8,228) | $(7,946) |
| Cash and Cash Equivalents (Year End) | $2,496 | $2,371 |
| Accumulated Deficit | $(168,349) | $(160,121) |
| Net Cash Used in Operating Activities | $(7,436) | $(7,886) |
| Net Cash Provided by Financing Activities | $7,568 | $9,160 |
Note: The filing text does not provide specific gross margin or operating margin percentages due to the absence of revenue in 2025.
Material Changes vs. Prior Period
- Revenue: Revenue dropped to $0 in 2025 from $58,000 in 2024. The company generates modest revenue from biotherapeutic delivery partnering agreements, which are inconsistent.
- Expenses: Total costs and expenses increased slightly to $8.3 million in 2025 from $8.1 million in 2024. R&D expenses rose by approximately $575,000 due to closeout activities for the CardiAMP Heart Failure Trial and enrollment in the CardiAMP Heart Failure II Trial. SG&A expenses decreased by approximately $356,000 due to lower professional service fees and share-based compensation.
- Liquidity: Cash balances remained relatively stable, ending 2025 at approximately $2.5 million. The company raised approximately $8.7 million in gross proceeds from equity sales in 2025 (including a $6.0 million registered offering in September).
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Clinical Progress: The CardiAMP HF Phase III trial did not meet its primary endpoint but showed compelling signals of benefit in a prespecified subgroup of patients with elevated NTproBNP biomarkers (47% relative risk reduction in heart death equivalents). Echocardiography results presented in March 2026 showed positive evidence of decreased pathological left ventricular remodeling in treated patients.
- Regulatory Strategy: The company is exploring approval in the U.S. (FDA) and Japan (PMDA) based on existing data, potentially requiring post-marketing studies. A Q-Sub request is expected to be filed with the FDA. A formal clinical consultation with PMDA is scheduled for Q2 2026.
- Future Trials: Enrollment is ongoing for the CardiAMP HF II confirmatory trial (up to 250 patients) and the CardiAMP Chronic Myocardial Ischemia trial (up to 343 patients).
Risks and Contingencies
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. With approximately $2.5 million in cash, the company believes funds are insufficient to meet obligations beyond May 2026 without additional financing.
- Capital Requirements: The company requires substantial additional financing to achieve its goals. Failure to obtain capital could force delays or termination of product development.
- Regulatory Uncertainty: Approval is not guaranteed. The CardiAMP Cell Therapy System is the first cardiac cell-based therapy regulated via the PMA pathway, creating uncertainty regarding the approval process.
- Nasdaq Listing: The company is not currently in compliance with the Nasdaq minimum stockholders' equity requirement ($2.5 million) and faces potential delisting risks.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure funding before May 2026 to avoid operational cessation.
- Regulatory Pathway: Confirm the outcome of the FDA Q-Sub request and the PMDA clinical consultation scheduled for Q2 2026.
- Clinical Data Interpretation: Review the full data regarding the CardiAMP HF trial's primary endpoint failure versus the positive subgroup analysis to assess commercial viability.
- Dilution Risk: Monitor upcoming equity offerings (including the ATM facility) which may be highly dilutive to existing shareholders.
- Nasdaq Compliance: Track the company's progress in regaining compliance with Nasdaq listing standards to avoid delisting.